UC Davis clinical trial shows biomarkers hold clue in treating aggressive prostate cancer Dr. Kamal Kant Kohli17 Jun 2025 8:30 PM ISTMany men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical trial at UC Davis...
Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma20 Dec 2023 2:30 PM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
Janssen bags USFDA nod for Akeega to treat prostate cancer Ruchika Sharma12 Aug 2023 11:35 AM ISTHorsham: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food & Drug Administration (FDA) has...
FDA approves niraparib regimen for BRCA-mutated metastatic castration-resistant prostate cancer Dr. Kamal Kant Kohli12 Aug 2023 10:15 AM ISTThe Food and Drug Administration has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with...
Janssen gets European Commission nod for AKEEGA to treat metastatic castration resistant prostate cancer with BRCA1/2 mutations Ruchika Sharma22 April 2023 11:32 AM ISTThe EC authorisation, which also marks the first worldwide approval for AKEEGA, is based on results of the randomised, double-blind, placebo...
Janssen seeks USFDA nod for Niraparib and Abiraterone Acetate Dual-Action Tablet, plus Prednisone to treat patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations Ruchika Sharma2 March 2023 3:15 PM ISTMetastatic castration-resistant prostate cancer characterizes cancer that no longer responds to androgen deprivation therapy and has spread to other...
GSK gets CDSCO Panel nod to market anticancer Niraparib Tablet Susmita Roy12 Oct 2022 6:00 PM ISTNew Delhi: Granting the proposal of a local clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard...
GSK announces USFDA committee to review Zejula overall survival data from NOVA phase III trial in recurrent ovarian cancer Ruchika Sharma24 Sept 2022 5:41 PM ISTUK: GSK plc has announced that the US Food and Drug Administration (USFDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to...
GSK gets USFDA approval for Ovarian Cancer Drug Zejula Ruchika Sharma2 May 2020 9:30 AM ISTLondon: GlaxoSmithKline plc has announced the US Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA)...
